65 related articles for article (PubMed ID: 38342420)
1. Interleukin-17A educated hepatic stellate cells promote hepatocellular carcinoma occurrence through fibroblast activation protein expression.
Ni JS; Fu SY; Wang ZY; Ding WB; Huang J; Guo XG; Gu FM
J Gene Med; 2024 Jun; 26(6):e3693. PubMed ID: 38860366
[TBL] [Abstract][Full Text] [Related]
2. METTL14 downregulation drives S100A4
Wang YF; Zhang WL; Li ZX; Liu Y; Tan J; Yin HZ; Zhang ZC; Piao XJ; Ruan MH; Dai ZH; Wang SJ; Mu CY; Yuan JH; Sun SH; Liu H; Yang F
Signal Transduct Target Ther; 2024 Apr; 9(1):91. PubMed ID: 38627387
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
Sotoudeheian M
Protein Pept Lett; 2024 May; ():. PubMed ID: 38715329
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence imaging sheds light on the immune evasion mechanisms of hepatic stellate cells mediated by superoxide anion.
Mao Y; Wu C; Wang X; Zhang F; Qi X; Li X; Li P; Tang B
Commun Biol; 2024 May; 7(1):558. PubMed ID: 38730013
[TBL] [Abstract][Full Text] [Related]
5. Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis.
Crane H; Eslick GD; Gofton C; Shaikh A; Cholankeril G; Cheah M; Zhong JH; Svegliati-Baroni G; Vitale A; Kim BK; Ahn SH; Kim MN; Strasser S; George J
Clin Mol Hepatol; 2024 Apr; ():. PubMed ID: 38623613
[TBL] [Abstract][Full Text] [Related]
6. Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.
Lu H; George J; Eslam M; Villanueva A; Bolondi L; Reeves HL; McCain M; Chambers E; Ward C; Sartika D; Sands C; Maslen L; Lewis MR; Ramaswami R; Sharma R
Liver Cancer; 2023 Feb; 12(1):19-31. PubMed ID: 36872928
[TBL] [Abstract][Full Text] [Related]
7. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease.
Gish R; Fan JG; Dossaji Z; Fichez J; Laeeq T; Chun M; Boursier J
Hepatol Int; 2024 Jun; ():. PubMed ID: 38850496
[TBL] [Abstract][Full Text] [Related]
8. Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.
Fu Y; Wang Z; Qin H
Metabolites; 2024 Apr; 14(4):. PubMed ID: 38668346
[TBL] [Abstract][Full Text] [Related]
9. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M; Kim JY
Mol Oncol; 2024 Jun; ():. PubMed ID: 38874196
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review.
Ghazanfar H; Javed N; Qasim A; Zacharia GS; Ghazanfar A; Jyala A; Shehi E; Patel H
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539547
[TBL] [Abstract][Full Text] [Related]
11. Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology.
Du K; Jun JH; Dutta RK; Diehl AM
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619452
[TBL] [Abstract][Full Text] [Related]
12. The contribution of genetics and epigenetics to MAFLD susceptibility.
Moretti V; Romeo S; Valenti L
Hepatol Int; 2024 Apr; ():. PubMed ID: 38662298
[TBL] [Abstract][Full Text] [Related]
13. MAFLD Is A Ubiquitous Latent Cofactor in Viral- and Alcoholic-related Hepatocellular Carcinoma.
Nakamura T; Nakano M; Tsutsumi T; Amano K; Kawaguchi T
Clin Mol Hepatol; 2024 May; ():. PubMed ID: 38768960
[No Abstract] [Full Text] [Related]
14. Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.
De Cól JP; de Lima EP; Pompeu FM; Cressoni Araújo A; de Alvares Goulart R; Bechara MD; Laurindo LF; Méndez-Sánchez N; Barbalho SM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612504
[TBL] [Abstract][Full Text] [Related]
15. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.
Sun YD; Zhang H; Li YM; Han JJ
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189086. PubMed ID: 38342420
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
Myojin Y; Hikita H; Sugiyama M; Sasaki Y; Fukumoto K; Sakane S; Makino Y; Takemura N; Yamada R; Shigekawa M; Kodama T; Sakamori R; Kobayashi S; Tatsumi T; Suemizu H; Eguchi H; Kokudo N; Mizokami M; Takehara T
Gastroenterology; 2021 Apr; 160(5):1741-1754.e16. PubMed ID: 33346004
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts.
Zhou Y; Ren H; Dai B; Li J; Shang L; Huang J; Shi X
J Exp Clin Cancer Res; 2018 Dec; 37(1):324. PubMed ID: 30591064
[TBL] [Abstract][Full Text] [Related]
18. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma.
Wu M; Miao H; Fu R; Zhang J; Zheng W
Curr Mol Pharmacol; 2020; 13(4):261-272. PubMed ID: 32091349
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
